Marie-Jeanne Vrancken Peeters

8PUBLICATIONS
73CO-AUTHORS
Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Conflict of laws (incl. private international law)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 05, 2026
Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.

|Nov 07, 2024
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.

Giacomo Montagna, Alison Laws, Massimo Ferrucci

|Jun 12, 2024
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.

Josefien P van Olmen, A Marjolein Schrijver, Marcel P M Stokkel

|May 25, 2024
Resection Ratios and Tumor Eccentricity in Breast-Conserving Surgery Specimens for Surgical Accuracy Assessment.

Dinusha Veluponnar, Behdad Dashtbozorg, Marcos Da Silva Guimaraes

|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso

|Sep 09, 2023
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

Sonja Vliek, Florentine S Hilbers, Erik van Werkhoven

Pageof 2

Frequent Collaborators

2 joint publications

Behdad Dashtbozorg

2 joint publications

Gary J R Cook

2 joint publications

John Patrick Pilkington Woll

2 joint publications

Theo Ruers